Based on the data described in Section 3.1 and Section 3.2, it is possible to conclude that NK1R ligands, labelled with diagnostic/therapeutic radionuclides, can be applied for imaging or therapy of cancers overexpressing the NK1Rs and for that these receptor radiopharmaceuticals are efficacious. Here, TACR1 is linked to cancer.